Patients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving investigational agents at time of registration, or at any time while on study and during the 4 weeks preceding enrollmentXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXUse of any other investigational or study agentsXx_NEWLINE_xXUse of investigational cancer agents within 6 weeks prior to diagnosisXx_NEWLINE_xXPatients may not be receiving any other investigational agents while on studyXx_NEWLINE_xXPatients must not currently be receiving any other investigational agentsXx_NEWLINE_xXPatients must not be receiving any other investigational anti-cancer agents while on studyXx_NEWLINE_xXPatients must not receive any other investigational agents while on study or within four weeks prior to registrationXx_NEWLINE_xXPatients may not be receiving any other investigational agents while on studyXx_NEWLINE_xXPatients must not be receiving or planning to receive any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents while on study treatmentXx_NEWLINE_xXParticipants who are receiving or have received any other investigational agents within 14 days of enrollmentXx_NEWLINE_xXSubject is currently being treated with other investigational agents.Xx_NEWLINE_xXPatients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)Xx_NEWLINE_xXPatients receiving ongoing treatment with any other investigational agents are not eligibleXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients may not be receiving or have received any other investigational agents during/or within 1 month priorXx_NEWLINE_xXParticipants may not be receiving any other investigational agents; patients may not be receiving any other treatment for their rectal cancer during study participation and within 30 days prior to study treatmentXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents are excludedXx_NEWLINE_xXSubjects who are receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents or any other anti-cancer therapyXx_NEWLINE_xXConcurrent use of other investigational agentsXx_NEWLINE_xXEXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients receiving any other investigational agentsXx_NEWLINE_xXEXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agents during the proposed treatment cycle.Xx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other concurrent investigational agents, or have received any investigational agent within four weeks of commencing this protocol.Xx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatient is receiving any other investigational agents.Xx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents concurrentlyXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients may not receive any concurrent investigational agents while on studyXx_NEWLINE_xXPatients receiving ongoing treatment with any other investigational agents are not eligibleXx_NEWLINE_xXConcurrent use of any other investigational agentsXx_NEWLINE_xXCurrent or anticipated use of other investigational agents during the studyXx_NEWLINE_xXReceiving other investigational agents or not yet completed 30 days since completion of an investigational studyXx_NEWLINE_xXPatients who are receiving concurrent investigational therapy;Xx_NEWLINE_xXSubjects may not be receiving any investigational agents within 30 days prior to start of study treatmentXx_NEWLINE_xXParticipants may not be receiving any other investigational study agents or treatment for their cancerXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXConcurrent administration of any other investigational agentsXx_NEWLINE_xXCurrently receiving radiotherapy, biological therapy, or any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agents.Xx_NEWLINE_xXPatients receiving any other investigational agents.Xx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXPatients must not be receiving any other investigational agentsXx_NEWLINE_xXConcurrent use of any other anti-cancer agents or treatments or any other investigational agentsXx_NEWLINE_xXConcurrent use of any other anti-cancer agents or treatments or any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents for their lymphomaXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXConcurrent treatment with any other investigational therapeutic agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agents within 21 days of the first dose of study drugXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents concurrentlyXx_NEWLINE_xXParticipant receiving any other investigational agents within 30-days of enrollment nor during study participationXx_NEWLINE_xXPatients may not be receiving any other investigational agents; (i.e. 28-day washout period from prior investigational drug is required)Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapyXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXReceiving concurrent investigational therapyXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents, or have received an investigational agent within the past 30 daysXx_NEWLINE_xXOther investigational agents: ?4 weeksXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are concurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational therapyXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents are excludedXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other anti-neoplastic investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other therapeutic investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or have received investigational agents within 4 weeks of beginning treatmentXx_NEWLINE_xXPatients may not be receiving (or received prior to enrollment) any other investigational agents for metastatic disease.Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents for treatment of their kidney cancerXx_NEWLINE_xXPatients who are receiving other investigational agentsXx_NEWLINE_xXNo other concurrent investigational agents are allowedXx_NEWLINE_xXPatients who are actively receiving any other investigational agentsXx_NEWLINE_xXSubjects may not receive any other concomitant investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXConcurrent use of other investigational agentsXx_NEWLINE_xXPatient must not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients receiving concurrent investigational chemotherapeutic agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents or other tumor-directed therapy.Xx_NEWLINE_xXSubjects who are receiving any other investigational agents. Prior immunotherapy, topotecan and temozolomide are allowedXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving other investigational agents.Xx_NEWLINE_xXPatients who are receiving any other investigational agents.Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatient is receiving other investigational agentsXx_NEWLINE_xXPatients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents).Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSTRATUM A: Participants receiving any other investigational agentsXx_NEWLINE_xXSTRATUM B: Participants receiving any other investigational agentsXx_NEWLINE_xXSTRATUM C: Participants receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents.Xx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents concurrentlyXx_NEWLINE_xXPatients may not be receiving any other investigational agents for the treatment of their breast cancerXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agents targeting histiocytosisXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chairXx_NEWLINE_xXPatients who are receiving any other anticancer or investigational agentsXx_NEWLINE_xXPatients must not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents within 30 days of registrationXx_NEWLINE_xXPatients must not be receiving any other investigational agentsXx_NEWLINE_xXCurrent or anticipated use of other investigational agentsXx_NEWLINE_xXPatients receiving other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational drug therapyXx_NEWLINE_xXReceiving any other investigational agents or any other anti-cancer therapyXx_NEWLINE_xXPatients may not be receiving any other investigational agents.Xx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects who are receiving any other investigational agentsXx_NEWLINE_xXSubjects concurrently receiving any other investigational agents within 2 weeks prior to the first study treatmentXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents.Xx_NEWLINE_xXPatients who are receiving any other investigational agents.Xx_NEWLINE_xXPatients who are currently receiving or have previously received any other investigational agents within 3 weeks prior to entering the studyXx_NEWLINE_xXParticipants who are receiving any other investigational agents, or any other anti-cancer therapy during study treatmentXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatient is receiving other investigational drugsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents =< 28 days prior to study treatmentXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents within 30 days of receiving zydeligXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents, or has received an investigational agent within the last 30 daysXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any concurrent investigational agentsXx_NEWLINE_xXPatients who are receiving any investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents or other tumor-directed therapyXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents; a 2 week wash-out period for investigational agents is required before registrationXx_NEWLINE_xXSubjects may not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXConcomitant use of other investigational agents.Xx_NEWLINE_xXPatients who are receiving any other investigational agents within 28 days before start of study treatmentXx_NEWLINE_xXSubjects may not be receiving other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents =< 14 days from registrationXx_NEWLINE_xXPatients who are receiving any other investigational agents or have within the last 28 daysXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents within 14 days prior to enrollmentXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents; any prior investigational agents must be stopped at least 14 days (2 week washout) prior to registrationXx_NEWLINE_xXPatients who are receiving any other investigational agents are ineligibleXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients should not have received any other investigational agents within the past 4 weeksXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXTreatment with other investigational agents within 30 days of day 1Xx_NEWLINE_xXSubjects receiving other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents for the treatment of non-small cell lung cancerXx_NEWLINE_xXPatients are permitted to receive investigational imaging agents while on studyXx_NEWLINE_xXPatients who are receiving any other investigational agents (with exception of imaging agents)Xx_NEWLINE_xXPatients who are receiving any other investigational agents; however, prior enrollment on a study using investigational agents is acceptableXx_NEWLINE_xXPatients who are receiving any other investigational agents within the preceding 4 weeksXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapyXx_NEWLINE_xXCurrently receiving any other investigational agents or received any within the past 28 daysXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents, or have received an investigational agent within the past 30 daysXx_NEWLINE_xXPatients receiving any other investigational agents or immunotherapyXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents within the preceding 4 weeksXx_NEWLINE_xXPatients receiving any other investigational chemotherapeutic agents within 28 days prior to the first dose of trial treatmentXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXPatients who are currently receiving any other investigational agents.Xx_NEWLINE_xXPatients who are receiving any investigational agentsXx_NEWLINE_xXPatients who are receiving any investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational or standard antineoplastic agentsXx_NEWLINE_xXPatients receiving any other investigational agents or are unable to be treated with doxorubicin, cyclophosphamide, and paclitaxelXx_NEWLINE_xXSubjects who are currently receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXSubjects who are actively receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXUse of any investigational agents within 21 days of registration.Xx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents.Xx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXJUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): patients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXConcurrent use of any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents within 4 weeks of the start of the study treatment.Xx_NEWLINE_xXCurrently receiving any investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents and or more that two different chemotherapy regimens for treatment of metastatic diseaseXx_NEWLINE_xXSubjects may not be receiving any other investigational agents or anticancer therapies.Xx_NEWLINE_xXCurrently receiving radiotherapy, biological therapy, or any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational and/or anti-cancer agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXCurrent therapy with any other investigational agents.Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeksXx_NEWLINE_xXSubjects who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrent or anticipated use of other investigational agentsXx_NEWLINE_xXInvestigational agents/therapiesXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agents that are intended as treatments of the relapsed tumorXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPast history of other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents with the intent to treat the disease (imaging agents are acceptable)Xx_NEWLINE_xXPatients who are receiving concurrent chemotherapy, or who are currently receiving other investigational chemotherapeutic agents or concurrently receiving radiationXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational therapeutic agentsXx_NEWLINE_xXSubjects may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving other investigational therapeutic agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXOngoing use of investigational agents or use of investigational agents within the last four weeksXx_NEWLINE_xXAre being treated with other investigational agents.Xx_NEWLINE_xXPatients may not be receiving any other investigational agents; use of over-the-counter herbal medications will also be excludedXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibitedXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational or standard antineoplastic agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients must not have received any investigational agents within 21 days of study entryXx_NEWLINE_xXCurrently receiving any investigational agents or received any tumor vaccines within the previous 6 weeksXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXSubjects is receiving any other investigational agents for the treatment of prostate cancerXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXSubjects must not be receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents.Xx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXMust not be receiving any other investigational agents within 14 days of first dose of azacitidine (day 7)Xx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXConcurrent use of any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents and/or other therapy for their cancerXx_NEWLINE_xXParticipants may not be receiving any other study agents, and may not have received any other investigational agents within 6 months prior to study entryXx_NEWLINE_xXPatients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapiesXx_NEWLINE_xXPatient must not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational cancer treatment agents at the time of enrollmentXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other study agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXEXCLUSION CRITERIA FOR REGISTRATION: patients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any investigational agents or received any tumor vaccines within the previous six weeksXx_NEWLINE_xXThe use of other concurrent investigational agents will not be allowedXx_NEWLINE_xX-  Investigational Agents: Investigational agents within 4 weeks (or 5 half-lives) of PV-10 administration.Xx_NEWLINE_xXSimultaneous primary invasive cancers or patients currently receiving any other investigational agents at time of study enrollment. Patients may have received investigational agents in the past. No washout time period is required.Xx_NEWLINE_xXPatient may not be receiving any other investigational drugXx_NEWLINE_xXCurrent receipt of any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are currently receiving any other investigational agents.Xx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not have received any other investigational agents in the previous 3 monthsXx_NEWLINE_xXUse of other investigational agents within 6 months prior to enrollmentXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXConcomitant use of other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents within 4 weeks of beginning study treatmentXx_NEWLINE_xXPatients concurrently receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational or standard antineoplastic agentsXx_NEWLINE_xXPatients who have received any other investigational agents within the preceding 4 weeksXx_NEWLINE_xXCurrently receiving any other investigational agents.Xx_NEWLINE_xXConcurrent use of other investigational agentsXx_NEWLINE_xXTreatment with other investigational agents within 30 days of day 1Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents =< 28 days prior to registrationXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any investigational agents are not eligibleXx_NEWLINE_xXParticipants receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXSubjects who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXThe subject is receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients may not currently be receiving any other investigational agents for leukemiaXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXTREATMENT: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatmentXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrent or anticipated use of other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients must not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agents for treatment of their cancerXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other biologic, cytotoxic or investigational agentsXx_NEWLINE_xXAny other investigational agents within the past 4 weeksXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollmentXx_NEWLINE_xXSubjects may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXConcurrent use of any other investigational agentsXx_NEWLINE_xXOngoing use of any other investigational or study agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving or have received any other  investigational agents during or within 1 month prior to treatment with NFVXx_NEWLINE_xXReceiving other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapyXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrent or anticipated use of other investigational agentsXx_NEWLINE_xXSubjects who are concurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who have received any other investigational agents within the last 4 weeksXx_NEWLINE_xXPatients may not be receiving any additional investigational agents or radiation therapyXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapyXx_NEWLINE_xXPatients receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapyXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to registrationXx_NEWLINE_xXPHASE II: Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to randomizationXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXConcurrent administration of any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents within 4 weeks of starting the study treatment and during the study periodXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatient is receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapyXx_NEWLINE_xXPatients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents for melanomaXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollmentXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrent use of any investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents are not eligibleXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXTreatment with other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPHASE II: Patients may not be receiving any other investigational agents while on studyXx_NEWLINE_xXConcurrent treatment with other investigational agents is not permittedXx_NEWLINE_xXPatients must not be receiving any other investigational agentsXx_NEWLINE_xXPatients currently receiving other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any investigational agents or have received any tumor vaccines within the previous six weeksXx_NEWLINE_xXMay not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants receiving any other investigational agentsXx_NEWLINE_xXPrior use of systemic investigational agents for HCCXx_NEWLINE_xXConcurrent use of other investigational agents.Xx_NEWLINE_xXPatients who are receiving any other investigational agents for cancerXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXActive treatment with any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients may not be planning to receive any other investigational agentsXx_NEWLINE_xXPatients must not be planning to receive other anti-cancer agents including investigational agents while on protocol treatmentXx_NEWLINE_xXSubject who is receiving any other investigational agents;Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXNot receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXReceiving any investigational agents currently or within 30 days prior to study screeningXx_NEWLINE_xXPatients must not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not have received any other investigational agents within 4 weeks of study entryXx_NEWLINE_xXPatients may not receive any other concurrent investigational agents while on studyXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects who are receiving or have received any other investigational agents within 28 days prior to day 1 of treatment in this studyXx_NEWLINE_xXPatients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollmentXx_NEWLINE_xXConcomitant use of other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrent or anticipated use of other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents at the time of registrationXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients must not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXUse of any other investigational agentsXx_NEWLINE_xXCurrently receiving any investigational agents or have received any tumor vaccines within previous 4 weeksXx_NEWLINE_xXConcurrent treatment with other investigational agentsXx_NEWLINE_xXCurrently receiving any investigational agents or received any tumor vaccines within the previous six weeksXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrent use of other investigational agentsXx_NEWLINE_xXUse of investigational agents within 30 daysXx_NEWLINE_xXCurrently receiving any other active investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agents after ASCTXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents\r\n* Note: a wash-out period of 2 weeks prior to registration is required for any patient to be enrolled in the studyXx_NEWLINE_xXParticipants may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeksXx_NEWLINE_xXPatients may not be receiving any other investigational agents within 2 weeks prior to registrationXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatient receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational cancer-directed agentsXx_NEWLINE_xXActively receiving any investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents within 30 days prior to the first dose of trial treatmentXx_NEWLINE_xXParticipants who are receiving any other investigational agents within 14 days before the first dose of study drugXx_NEWLINE_xXPatients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) other than temozolomideXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXUse of any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXConcurrent use of any other investigational agents.Xx_NEWLINE_xXPatients receiving other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents concurrently with study treatmentXx_NEWLINE_xXPatients receiving any other investigational agents or any additional anti-cancer agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXSubjects receiving other investigational agents are not eligibleXx_NEWLINE_xXMay not be receiving any other study agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollmentXx_NEWLINE_xXOther concurrent investigational agents;Xx_NEWLINE_xXResearch participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapyXx_NEWLINE_xXPatients may not be on any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPHASE II: Participants may not be receiving any other investigational agentsXx_NEWLINE_xXConcurrent therapy with other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any biologics or investigational agents within 3 weeksXx_NEWLINE_xXPatients who are receiving any other investigational agents or who have received pomalidomide in the pastXx_NEWLINE_xXSubjects may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrent or prior treatment for this cancer with immunotherapy and/or any other investigational agentsXx_NEWLINE_xXPatients should not be receiving any other investigational agentsXx_NEWLINE_xXOngoing therapy with other investigational agents. Patients may not be receiving any other investigational agents.Xx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological chemotherapyXx_NEWLINE_xXParticipants may not be receiving any other investigational agents; concurrent treatment with bisphosphonates or denosumab is allowedXx_NEWLINE_xXParticipants receiving any other study agentsXx_NEWLINE_xXPatients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)Xx_NEWLINE_xXConcurrent treatment with other investigational or anti-neoplastic agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational anticancer agentsXx_NEWLINE_xXConcurrent use of other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agents that are intended as treatments of GBMXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients receiving any other investigational agents for cancer treatmentXx_NEWLINE_xXPatients may not be receiving any other investigational agents while on study treatmentXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXTreatment with other investigational agents =< 14 days of registrationXx_NEWLINE_xXParticipants may not be receiving any other study agents.Xx_NEWLINE_xXPatients who are currently receiving any other investigational agents.Xx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents while on studyXx_NEWLINE_xXPatient receiving any other investigational agentsXx_NEWLINE_xXPatient must not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any investigational agentsXx_NEWLINE_xXPatients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than androgen deprivationXx_NEWLINE_xXPatient must not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any investigational agents or registration on another therapy based trialXx_NEWLINE_xXPatients who are receiving any investigational agents.Xx_NEWLINE_xXANY concurrent investigational agentsXx_NEWLINE_xXCurrent or anticipated use of other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients receiving any other chemotherapy or investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents; any prior investigational products must be stopped at least 14 days (2-week washout) prior to registrationXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXNo concurrent methotrexate, thiotepa, cytarabine, or investigational agentsXx_NEWLINE_xXSubjects may not receive any other concomitant investigational agentsXx_NEWLINE_xXSubjects receiving any other investigational agentsXx_NEWLINE_xXParticipants who are currently receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXTreatment with other investigational agents in the prior 4 weeks.Xx_NEWLINE_xXUse of investigational agents within 4 weeks prior to enrollmentXx_NEWLINE_xXAny investigational agentsXx_NEWLINE_xXSubjects receiving other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXConcurrent treatment with other investigational agents(s)Xx_NEWLINE_xXTreatment with other investigational agents within 30 days of day 1Xx_NEWLINE_xXPatients may not be receiving any other investigational agents.Xx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents including those for symptom managementXx_NEWLINE_xXReceiving any other investigational agents currently, or within time limits specified above prior to study day 1Xx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients receiving other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents nor have received any investigational drug 30 days prior to enrollmentXx_NEWLINE_xXParticipants who are receiving concurrent therapy with other investigational agentsXx_NEWLINE_xXPatient receiving any investigational or experimental agents other than checkpoint blockade immunotherapyXx_NEWLINE_xXPatients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapiesXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients should not be receiving any other investigational agentsXx_NEWLINE_xXPatients must not be receiving other investigational agents or concurrent anticancer therapyXx_NEWLINE_xXPatients should not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents or commercial agents with the intent to treat the malignancyXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXOther investigational agents: ?4 weeksXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are currently receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents.Xx_NEWLINE_xXPatients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)Xx_NEWLINE_xXPatient must not have received treatment with other investigational agents within the last 4 weeksXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXNo other concurrent investigational agentsXx_NEWLINE_xXPatients must have discontinued immunotherapy or other systemic therapy including investigational agents at least 4 weeks prior to entering the study and have recovered from adverse events due to those agents. Patients must agree to not receive any other investigational agents during study participation.Xx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents or other medications for the treatment of their malignancyXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents concurrentlyXx_NEWLINE_xXPatients may not receive any other anti-neoplastic or investigational agents within 3 weeks of study enrollment; patients may not be receiving any other investigational agents during treatment on protocolXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational anti-cancer agentsXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrent receiving any other anti-neoplastic investigational agentsXx_NEWLINE_xXCurrent therapy with other investigational agents.Xx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agents or any other anti-cancer therapyXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents or have received immunotherapyXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollmentXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any additional investigational agents or radiation therapyXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXParticipants receiving any other anti-cancer or investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents within 28 days before start of study treatmentXx_NEWLINE_xXNo concurrent anti-cancer treatment (including topical agents such as imiquimod) or investigational agentsXx_NEWLINE_xXReceiving any other investigational agents simultaneously or within 3 weeks following ablation procedureXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents or active anti-neoplastic therapiesXx_NEWLINE_xXPatients may not be receiving any other investigational agents; a minimum 4 week washout period is requiredXx_NEWLINE_xXPatients should not be receiving any other investigational agentsXx_NEWLINE_xXInvestigational agents/therapiesXx_NEWLINE_xXInvestigational agents within 4 weeks of randomization.Xx_NEWLINE_xXUse of other investigational agents within 6 weeks of day 1 of protocol therapyXx_NEWLINE_xXParticipants may not be receiving other investigational agents.Xx_NEWLINE_xXInvestigational agents within 4 weeks before start of study therapyXx_NEWLINE_xXConcurrent use of other anti-cancer agents or treatments, including other investigational agentsXx_NEWLINE_xXPatients may not be receiving any investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatient must not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients currently receiving other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents.Xx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving concurrent investigational drugsXx_NEWLINE_xXPatients planning on receiving other investigational agents while on this studyXx_NEWLINE_xXPatients receiving other investigational therapiesXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents or have received other investigational agents for at least 3 weeksXx_NEWLINE_xXPatients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies except hormonal maintenance treatment for prostate cancerXx_NEWLINE_xXConcurrent use of investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXActively receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapyXx_NEWLINE_xXPatients may not be receiving any other investigational agents within 7 days of registrationXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXSubjects who are receiving any other investigational agentsXx_NEWLINE_xXAll cancer patients receiving chemotherapy agentsXx_NEWLINE_xXParticipants may not be receiving any other study agentsXx_NEWLINE_xXPatients currently receiving any other investigational agents;Xx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agents within 30 days of enrollment or during this studyXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects who are receiving any other investigational agents or have received another investigational drug in the last 30 daysXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXSubjects may not be receiving any investigational agentsXx_NEWLINE_xXResearch participants receiving any other investigational agentsXx_NEWLINE_xXNo restrictions on use of other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients receiving any other study agentsXx_NEWLINE_xXParticipants receiving any other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptableXx_NEWLINE_xXCurrent or anticipated use of other investigational agentsXx_NEWLINE_xXNo restrictions regarding use of other investigational agentsXx_NEWLINE_xXPatient must not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agents for treatment of GVHD or underlying disease for at least 7 daysXx_NEWLINE_xXPatient must not be actively receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapyXx_NEWLINE_xXPatients who are receiving other investigational agents will be permitted on study, at the discretion of the principal investigatorXx_NEWLINE_xXParticipants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionaryXx_NEWLINE_xXCurrent use of any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving investigational agentsXx_NEWLINE_xXReceiving any other investigational agents =< 6 months prior to registrationXx_NEWLINE_xXReceiving any other investigational agents =< 6 months prior to RegistrationXx_NEWLINE_xXActive use of any other investigational agentsXx_NEWLINE_xXCurrent use of any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXCurrent use of any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving investigational agents in a clinical trialXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXCurrently receiving investigational agents in a clinical trialXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXReceiving any other investigational, anticoagulation, and/or chemotherapy agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXCurrent use of any other investigational agentsXx_NEWLINE_xXParticipants receiving any other investigational agentsXx_NEWLINE_xXParticipant is receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants who are currently receiving any other investigational agents or have received investigational agents within the past 3 months will be excludedXx_NEWLINE_xXParticipants may not be receiving any other investigational agents within past 3 monthsXx_NEWLINE_xXParticipants may not have received any other investigational agents in the previous 3 monthsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXReceipt of any other investigational agents =< 3 months prior to randomization, except innocuous agents with no known interaction with the study agents (e.g., standard dose multivitamins or topical agents for limited skin conditions), at the discretion of the protocol lead investigator at each participating siteXx_NEWLINE_xXConcurrent therapy with investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agents; any prior investigational therapeutic products must be stopped at least 28 days (4 week washout) prior to treatment startXx_NEWLINE_xXPatients receiving any other investigational agents are ineligibleXx_NEWLINE_xXOngoing therapy with other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXHave received other investigational agents within the past 3 months (preceding the time of registration)Xx_NEWLINE_xXParticipants may not be receiving any other investigational agents during the studyXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXParticipants may not be receiving any other investigational agentsXx_NEWLINE_xXThere will be no restrictions regarding use of other investigational agentsXx_NEWLINE_xXThere will be no restrictions regarding use of other investigational agentsXx_NEWLINE_xXReceiving any other investigational agentsXx_NEWLINE_xXPatient may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agents (in the past 28 days) or herbal medication (within 1 day)Xx_NEWLINE_xXPatients must not receive any other investigational agents while on studyXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients should not be taking other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXCurrent use of any investigational agentsXx_NEWLINE_xXPatient must not be receiving an investigational drugXx_NEWLINE_xXPatients may not be currently receiving any other investigational agents within 4 weeks of study registrationXx_NEWLINE_xXPatients receiving any other study agentsXx_NEWLINE_xXPatients must not currently be using other investigational agentsXx_NEWLINE_xXParticipants receiving other investigational agentsXx_NEWLINE_xXParticipants who are receiving any other investigational agentsXx_NEWLINE_xXWomen who are receiving any other investigational agentsXx_NEWLINE_xXPatients should not be taking other investigational agentsXx_NEWLINE_xXReceiving any investigational agentsXx_NEWLINE_xXSubjects may not be receiving any investigational agentsXx_NEWLINE_xXCurrent receipt of any other investigational agents or any additional anti-cancer agents for this or any other diseaseXx_NEWLINE_xXConcurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocolXx_NEWLINE_xXPatients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 1 day)Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXOngoing treatment with any other investigational agentsXx_NEWLINE_xXPatients receiving any other investigational agents within 4 weeks of starting the studyXx_NEWLINE_xXReceipt of any other investigational agents or any additional anti-cancer agentsXx_NEWLINE_xXPatients may not be receiving any other investigational agentsXx_NEWLINE_xXDonors receiving experimental therapy or investigational agents.Xx_NEWLINE_xXPatients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 7 days)Xx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xXPatients who are receiving any other investigational agentsXx_NEWLINE_xX